Unfortunately, clinical evaluation and diagnostic tests sometimes fail to determine whether a necrotizing myopathy is immune mediated, resulting in undertreatment of autoimmune myopathies or ...
CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...
Can We Differentiate Those Who Have the Self-limited Form of Statin Myopathy From Those Who Have the Immune-Mediated Variety? In our experience, most patients with autoimmune statin myopathy had ...